产品名称 AS 1892802
产品货号 Axon 2187 CAS [928320-12-1] MF C20H19N3O2MW 333.38 Purity: 100% Optical purity: >99% e.e. Soluble in DMSO Description Potent, selective, ATP-competitive, and orally active ROCK inhibitor (in vitro IC50 values 1.69 μM and 0.10 μM for ROCK1 and ROCK2 resp.) that reduces both inflammatory and non-inflammatory pain in rat models. Another group published IC50 values of 122, 52, and 57 nM for human ROCK1, ROCK2, and rat ROCK2 respectively. AS 1892802 dose dependently prevented the formation of tibial cartilage lesions due to MIA induction of osteoarthritis (OA), and completely inhibited IL-1α–induced PGE2 production. Additionally, it potently inhibited the phosphorylation of the ROCK substrate MLC2 in intact human breast cancer cells. References Certificates Categories Extra info R. Li et al. Fragment-Based and Structure-Guided Discovery and Optimization of Rho Kinase Inhibitors. J. Med. Chem. 2012, 55, 2474−2478.     N. Takeshita et al. Alleviating Effects of AS1892802, a Rho Kinase Inhibitor, on Osteoarthritic Disorders in Rodents. J. Pharmacol. Sci. 2011, 115, 481–489. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology Stem Cell ROCK TGF-β EC 2.7.11.1 Potent, selective, ATP-competitive ROCK inhibitor Chemical name (S)-1-(2-hydroxy-1-phenylethyl)-3-(4-(pyridin-4-yl)phenyl)urea Parent CAS No. [928320-12-1] Order Size Unit Price Stock 5 mg €95.00 In Stock
产品价格 现货询价,电话:010-67529703
产品规格
产品品牌 axonmedchem
产品概述
产品详情

AS 1892802

Based on 15 reference(s) in Google Scholar 8 10 15

Axon 2187

CAS [928320-12-1]

MF C20H19N3O2
MW 333.38

  • Purity: 100%
  • Optical purity: >99% e.e.
  • Soluble in DMSO

AS 1892802

Description

Potent, selective, ATP-competitive, and orally active ROCK inhibitor (in vitro IC50 values 1.69 μM and 0.10 μM for ROCK1 and ROCK2 resp.) that reduces both inflammatory and non-inflammatory pain in rat models. Another group published IC50 values of 122, 52, and 57 nM for human ROCK1, ROCK2, and rat ROCK2 respectively. AS 1892802 dose dependently prevented the formation of tibial cartilage lesions due to MIA induction of osteoarthritis (OA), and completely inhibited IL-1α–induced PGE2 production. Additionally, it potently inhibited the phosphorylation of the ROCK substrate MLC2 in intact human breast cancer cells.
产品资料